28bio

Predict CNS neurotoxicity in human cortical organoids by measuring neuronal network disruption across small molecules, ASOs, and gene therapies.

Assay-ready human cortical organoids for CNS toxicity and efficacy studies measuring drug-induced changes in functional neuronal network activity.

Nexon, a neurotechnology platform powered by human brain organoids. Combining tissue engineering, neural interfacing, and AI-driven analytics,

Human brain organoids that learn and adapt, used to predict drug effects on learning and memory, power autonomous devices in low-connectivity environments, and enable low-energy computing.

Preclinical safety and efficacy assessments with CNS and PNS organoids. Application Notes for neurotoxicity, neurodegeneration, neurodevelopment, and more.

Organoid model resources for CNS and PNS safety and efficacy assessments. Scientific posters, application notes, webinars, and more.

Scientific posters feature human CNS and PNS organoid models for neurotoxicity testing, chemotherapy-induced neuropathy, disease modeling, and more.

The page provides protocols for human brain organoids, peripheral nervous system models, neurotoxicity testing, disease modeling, and preclinical drug development.

28bio today announced the Nexon neurotechnology platform—a major advancement in understanding human brain function. The platform integrates tissue engineering, neural interfacing and AI to engineer human brains at-scale and replicate complex neurological processes.

The page covers 28bio’s brain organoid innovations, clinical studies, and advances in CNS drug discovery, including case studies and industry news.

Latest news, press releases, and media coverage about 28bio's brain organoid technology, CNS-3D platform, and advances in neurological drug discovery.

The page features research spotlights on organoid intelligence, neurotoxicity testing, demyelinating disease modeling, and neurodegenerative disease grants.

28bio engineers human brains at scale to advance drug development and address neurological health challenges.

28bio is a neurotechnology company that engineers human brains at scale and aims to transform drug development and reverse the neurological health crisis.

AxoSim names Alif Saleh as CEO to advance commercialization. Former CEO Dr. Lowry Curley becomes Chief Scientific Officer to drive scientific innovation.

The page describes career opportunities at 28bio, focusing on science and mission-driven neurotechnology.

The page lists career opportunities at 28bio.

28bio’s platform creates living organs, including nerve tissues that signal, fire, and learn, using real human cells.

The page lists upcoming and past 28bio events, including conferences, webinars, and summits.

The company’s platform creates living organs, including organoids made from human cells, nerve tissues that signal, fire, and learn, and neural networks described as human biology.

Neurotoxicity testing and efficacy assessment with CNS and PNS organoids. FAQs explore how to get started, reproducibility, and shipping methods.

Integrating tissue engineering, neural interfacing, and AI to engineer human brain models with neurological functions, including memory, learning, and cognition.

Integrating tissue engineering, neural interfacing, and AI to engineer human brain models with neurological functions, including memory, learning, and cognition.

28bio’s Privacy Policy explains how the company collects, uses, protects, and manages personal information and website data.

28bio’s Financial Conflict of Interest Policy outlines disclosure requirements and compliance standards for research transparency.

The Central US hosts emerging neurotechnology clusters spanning regions like the Great Lakes and Gulf Coast. Local ecosystems integrate academic research, startups, and industry partnerships to advance brain-machine interfaces, diagnostics, and therapeutic solutions. Key hubs leverage existing infrastructure in cities such as Chicago, St. Louis, and Houston, fostering collaboration between universities and private-sector players.

Oct 2026theneurotechnewsletter.substack.comNews article

28bio introduces **CNS-3D Plasticity Organoids**, a tool for evaluating how drugs influence human learning and memory. The platform measures network potentiation and synaptic plasticity to serve as cognitive biomarkers. These assays aim to support drug development by assessing safety and efficacy in neurological contexts.

Aug 2026PR NewswireNews article

28bio introduces a **CNS-3D brain organoid assay** that models Alzheimer’s pathology by evaluating amyloid-driven damage and neuronal function. The platform aims to accelerate drug development by predicting how therapies interact with disease mechanisms in a 3D neural environment. Researchers can use it to test efficacy before advancing to clinical trials.

May 2026Yahoo FinanceNews article

28Bio uses brain organoids—clusters of lab-grown neural cells—to control video games like Pac-Man. The organoids, cultured in trays, generate real-time signals that guide in-game actions, demonstrating AI-like decision-making without traditional computing. This approach merges neuroscience with AI applications, potentially advancing brain-machine interfaces and datacenter-free processing.

Jun 2025corememory.comNews article